dr. rugo discusses a comparative review of trastuzumab biosimilars
Published 5 years ago • 198 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:43
dr. rugo discusses the equivalency of trastuzumab biosimilars
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
3:38
biosimilar trastuzumab
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
9:08
verzenio (abemaciclib) for breast cancer: who gets it? what are the side effects?
-
5:44
herceptin—a targeted antibody therapy for breast cancer
-
4:20
the biosimilar development process
-
1:35
dr. rugo on the optimal setting for biosimilar evaluation
-
6:25
hope s. rugo, et al.
-
3:18
trial of proposed trastuzumab biosimilar, myl-1401o vs herceptin
-
2:00
dr. rugo discusses advancements with biosimilars
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
1:41
dr. pegram on the development of trastuzumab biosimilars
-
12:12
breast cancer treatment - trastuzumab biosimilars
-
2:43
lilac: comparing cardiac safety of abp 980 with trastuzumab
-
1:00
dr. dang on the significance of the myl-1401o biosimilar in her2-positive metastatic breast cancer
-
0:51
dr. jhaveri on the use of trastuzumab biosimilars in breast cancer
-
1:47
the use of trastuzumab and biosimilars in the treatment of breast cancer
-
0:59
dr. verma discusses biosimilars for trastuzumab
-
1:02
dr. mitri on impact of trastuzumab biosimilar fda approval
-
3:49
novel strategies for her2 metastatic breast cancer; biosimilars